UK medtech needs to seize moment and make most of OLS
This article was originally published in Clinica
This month’s unveiling of the blueprint for the UK Office for Lifesciences (OLS) will be looked back on as a pivotal moment for the UK healthcare sector, writes Clinica principal analyst Ashley Yeo.
You may also be interested in...
The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.